# A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

> **NCT06661122** · — · RECRUITING · sponsor: **Bayer** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Low-volume Metastasis

## Interventions

- **DRUG:** Darolutamide (BAY1841788) + docetaxel + ADT

## Key facts

- **NCT ID:** NCT06661122
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2031-03-31
- **Final completion:** 2031-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06661122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06661122, "A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06661122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*